Nowell P, Hungerford D (1960) A minute chromosome in human chronic granulocytic leukemia. ScienceOpen, Berlin
Google Scholar
Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405):290–293
CAS
PubMed
Google Scholar
Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR et al (1983) Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306(5940):239–242
CAS
PubMed
Google Scholar
Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36(1):93–99
CAS
PubMed
Google Scholar
Vlaanderen J, Lan Q, Kromhout H, Rothman N, Vermeulen R (2012) Occupational benzene exposure and the risk of chronic myeloid leukemia: a meta-analysis of cohort studies incorporating study quality dimensions. Am J Ind Med 55(9):779–785
CAS
PubMed
Google Scholar
Rohrbacher M, Hasford J (2018) Epidemiology and etiology of chronic myeloid leukemia. In: Wiernik PH, Dutcher JP, Gertz MA (eds) Neoplastic diseases of the blood. Springer, Cham, pp 9–17
Google Scholar
Miranda-Filho A, Piñeros M, Ferlay J, Soerjomataram I, Monnereau A, Bray F (2018) Epidemiological patterns of leukaemia in 184 countries: a population-based study. Lancet Haematol 5(1):e14-24
PubMed
Google Scholar
Hochhaus A, Saussele S, Rosti G, Mahon F-X, Janssen JJWM, Hjorth-Hansen H et al (2017) Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:41–51
Google Scholar
Haznedaroğlu İC, Kuzu I, İlhan O (2020) WHO 2016 definition of chronic myeloid leukemia and tyrosine kinase inhibitors. Turk J Hematol 37(1):42–47
Google Scholar
Dorfman LE, Floriani MA, Oliveira TMRDR, Cunegatto B, Rosa RFM, Zen PRG (2018) The role of cytogenetics and molecular biology in the diagnosis, treatment and monitoring of patients with chronic myeloid leukemia. J Bras Patol E Med Lab 54(2):83–91
CAS
Google Scholar
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966–984
CAS
PubMed
PubMed Central
Google Scholar
Asnafi AA, Deris Zayeri Z, Shahrabi S, Zibara K, Vosughi T (2019) Chronic myeloid leukemia with complex karyotypes: prognosis and therapeutic approaches. J Cell Physiol 234(5):5798–5806
CAS
PubMed
Google Scholar
Rohan B, Purohit S, Lokanatha D, Jacob L, Suresh TM, Govind Babu K et al (2012) Chronic myeloid leukemia with variant chromosomal translocations: results of treatment with imatinib mesylate. J Health Allied Sci 11:1–4
Google Scholar
Hagemeijer A (1987) Chromosome abnormalities in CML. Baillières Clin Haematol 1(4):963–981
CAS
PubMed
Google Scholar
Shetty D, Talker E, Jain H, Talker J, Patkar N, Subramanian P et al (2021) Evaluation of cytogenetic response in CML patients with variant Philadelphia translocation. Asia Pac J Clin Oncol. https://doi.org/10.1111/ajco.13522
Article
PubMed
Google Scholar
Ankathil R, Ismail SM, Mohd Yunus N, Sulong S, Husin A, Abdullah AD et al (2020) Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era—a review. Malays J Pathol 42(3):307–321
CAS
PubMed
Google Scholar
Eyüpoğlu D, Bozkurt S, Haznedaroğlu İ, Büyükaşık Y, Güven D (2016) The impact of variant Philadelphia chromosome translocations on the clinical course of chronic myeloid leukemia. Turk J Hematol 33(1):60–65
Google Scholar
Trivedi P, Varma P, Patel D, Ladani D, Patel D, Kazi M et al (2019) Clinical implications of simultaneous occurrence of variant Philadelphia translocations in chronic myeloid leukemia. J Assoc Genet Technol 45(2):61–65
PubMed
Google Scholar
Sgherza N, Abruzzese E, Perla G, Minervini MM, Chiello V, Sciannamè N et al (2017) Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature. Ther Clin Risk Manag 27(13):751–755
Google Scholar
Mitelman F (1993) The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 11(Suppl 1):11–15
PubMed
Google Scholar
Benchikh S, Bousfiha A, Razoki L, Aboulfaraj J, Zarouf L, Elbakay C et al (2021) Chromosome abnormalities related to reproductive and sexual development disorders: a 5-year retrospective study. BioMed Res Int 5(2021):1–11
Google Scholar
Fröhling S, Döhner H (2008) Chromosomal abnormalities in cancer. N Engl J Med 359(7):722–734
PubMed
Google Scholar
Willatt L, Morgan S (2009) ISCN 2009 an international system for human cytogenetic nomenclature. Hum Genet 126:603–604
Google Scholar
Roche-Lestienne C, Boudry-Labis E, Mozziconacci M-J (2016) Cytogenetics in the management of “chronic myeloid leukemia”: an update by the Groupe francophone de cytogénétique hématologique (GFCH). Ann Biol Clin (Paris) 74(5):511–515
Google Scholar
Huegel A, Coyle L, McNeil R, Smith A (1995) Evaluation of interphase fluorescence in situ hybridization on direct hematological bone marrow smears. Pathology (Phila) 27(1):86–90
CAS
Google Scholar
Levsky JM, Singer RH (2003) Fluorescence in situ hybridization: past, present and future. J Cell Sci 116(Pt 14):2833–2838
CAS
PubMed
Google Scholar
Wolff DJ, Bagg A, Cooley LD, Dewald GW, Hirsch BA, Jacky PB et al (2007) Guidance for fluorescence in situ hybridization testing in hematologic disorders. J Mol Diagn 9(2):134–143
CAS
PubMed
PubMed Central
Google Scholar
Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R et al (2018) Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN 16(9):1108–1135
Google Scholar
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 122(6):872–884
CAS
PubMed
PubMed Central
Google Scholar
Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A et al (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30(8):1648–1671
CAS
PubMed
PubMed Central
Google Scholar
Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B et al (2020) Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 18(10):1385–1415
CAS
Google Scholar
Nestal de Moraes G, Souza PS, Costas FCF, Vasconcelos FC, Reis FRS, Maia RC (2012) The interface between BCR-ABL-dependent and -independent resistance signaling pathways in chronic myeloid leukemia. Leuk Res Treat 2012:19
Google Scholar
Patel AB, O’Hare T, Deininger MW (2017) Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am 31(4):589–612
PubMed
PubMed Central
Google Scholar
Zhao H, Deininger MW (2020) Declaration of Bcr-Abl1 independence. Leukemia 34(11):2827–2836
PubMed
Google Scholar
Zhou T, Medeiros LJ, Hu S (2018) Chronic myeloid leukemia: beyond BCR-ABL1. Curr Hematol Malig Rep 13(6):435–445
CAS
PubMed
Google Scholar
Braun TP, Eide CA, Druker BJ (2020) Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell 37(4):530–542
CAS
PubMed
PubMed Central
Google Scholar
Ding Y, Fan J, Fan Z, Zhang K (2021) γ-Tocotrienol reverses multidrug resistance of breast cancer cells through the regulation of the γ-Tocotrienol-NF-κB-P-gp axis. J Steroid Biochem Mol Biol 209:105835
CAS
PubMed
Google Scholar
Loscocco F, Visani G, Galimberti S, Curti A, Isidori A (2019) BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia. Front Oncol 9:939
PubMed
PubMed Central
Google Scholar
Jeanpierre S, Arizkane K, Thongjuea S, Grockowiak E, Geistlich K, Barral L et al (2021) The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission. Haematologica 106(1):111–122
CAS
PubMed
Google Scholar
O’Reilly E, Zeinabad HA, Nolan C, Sefy J, Williams T, Tarunina M et al (2021) Recreating the bone marrow microenvironment to model leukemic stem cell quiescence. Front Cell Dev Biol 9:2319
Google Scholar
Villatoro A, Konieczny J, Cuminetti V, Arranz L (2020) Leukemia stem cell release from the stem cell niche to treat acute myeloid leukemia. Front Cell Dev Biol 8:607
PubMed
PubMed Central
Google Scholar
Meggyesi N, Kozma A, Halm G, Nahajevszky S, Bátai Á, Fekete S et al (2012) Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients. Acta Haematol 127(1):34–42
PubMed
Google Scholar
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S et al (2020) High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia 34(8):2074–2086
CAS
PubMed
PubMed Central
Google Scholar
Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE et al (2016) Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 127(22):2742–2750
CAS
PubMed
PubMed Central
Google Scholar
Quintás-Cardama A, Cortes J (2009) Molecular biology of bcr-abl1–positive chronic myeloid leukemia. Blood 113(8):1619–1630
PubMed
PubMed Central
Google Scholar
Leguay T, Mahon F-X (2005) Leucémie myéloïde chronique. EMC Hématol 2(3):187–205
Google Scholar
Burmeister T, Reinhardt R (2008) A multiplex PCR for improved detection of typical and atypical BCR–ABL fusion transcripts. Leuk Res 32(4):579–585
CAS
PubMed
Google Scholar
Genthon A, Nicolini FE, Huguet F, Colin-Gil C, Berger M, Saugues S et al (2020) Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib. Oncotarget 11(26):2560–2570
PubMed
PubMed Central
Google Scholar
Nachi M, Kihel I, Entasoltane B, Brahimi M, Yafour N, Guella D et al (2020) Impact of the major BCR-ABL1 transcript type on clinical and biological parameters and molecular response in patients with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther. https://doi.org/10.1016/j.hemonc.2020.08.003
Article
PubMed
Google Scholar
Marcé S, Xicoy B, García O, Cabezón M, Estrada N, Vélez P et al (2021) Impact of BCR-ABL1 transcript type on response, treatment-free remission rate and survival in chronic myeloid leukemia patients treated with imatinib. J Clin Med 10(14):3146
PubMed
PubMed Central
Google Scholar
Arana-Trejo RM, Sánchez ER, Ignacio-Ibarra G, De La Fuente EB, Garces O, Morales EG et al (2002) BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML): BCR/ABL in CML Mexican patients. Clin Lab Haematol 24(3):145–150
CAS
PubMed
Google Scholar
Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi S-A, et al. Frequency of BCR-ABL fusion transcripts in iranian patients with chronic myeloid leukemia. 2008;5.
Muddathir AR, Kordofani A, Fadl-Elmula I (2013) Frequency of BCR-ABL fusion transcripts in Sudanese patients with chronic myeloid leukemia using real-time reverse transcription-polymerase chain reaction. Saudi Med J 9(34):29–33
Google Scholar
Uzoma IC, Taiwo IA, Nna EO, Durosinmi MA, Ukaejiofo EO (2019) Detection of BCR-ABL1 fusion gene transcripts in the saliva of Nigerian patients with chronic myeloid leukemia. Niger J Clin Pract 22(1):51–55
CAS
PubMed
Google Scholar
Paramita DK, Hutajulu SH, Syifarahmah A, Sholika TA, Fatmawati S, Aning S et al (2020) BCR-ABL gene transcript types of patients with chronic myelogenous leukemia in Yogyakarta, Indonesia. Asian Pac J Cancer Prev APJCP 21(6):1545–1550
PubMed
Google Scholar
Perrotti D, Calabretta B (2004) Translational regulation by the p210 BCR/ABL oncoprotein. Oncogene 23(18):3222–3229
CAS
PubMed
Google Scholar
Chalandon Y, Jiang X, Hazlewood G, Loutet S, Conneally E, Eaves A et al (2002) Modulation of p210BCR-ABL activity in transduced primary human hematopoietic cells controls lineage programming. Blood 99(9):3197–3204
CAS
PubMed
Google Scholar
Goldman JM, Melo JV (2003) Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med 349(15):1451–1464
CAS
PubMed
Google Scholar
Du Z, Lovly CM (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17(1):58
PubMed
PubMed Central
Google Scholar
Farkas DH, Holland CA (2009) Overview of molecular diagnostic techniques and instrumentation. Cell and tissue based molecular pathology. Elsevier, pp 19–32
Bustin SA, Mueller R (2005) Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin Sci 109(4):365–379
CAS
Google Scholar
Mir R, Ahmad I, Javid J, Zuberi M, Yadav P, Shazia R et al (2015) Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients. Indian J Cancer 52(3):314–318
PubMed
Google Scholar
Limsuwanachot N, Siriboonpiputtana T, Karntisawiwat K, Chareonsirisuthigul T, Chuncharunee S, Rerkamnuaychoke B (2016) Multiplex RT-PCR Assay for detection of common fusion transcripts in acute lymphoblastic leukemia and chronic myeloid leukemia cases. Asian Pac J Cancer Prev APJCP 17(2):677–684
PubMed
Google Scholar
Kitamura H, Tabe Y, Ai T, Tsuchiya K, Yuri M, Misawa S et al (2019) A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib. Jiang X, éditeur. PLoS ONE 14(3):170
Google Scholar
Ono T (2021) Which tyrosine kinase inhibitors should be selected as the first-line treatment for chronic myelogenous leukemia in chronic phase? Cancers 13(20):5116
CAS
PubMed
PubMed Central
Google Scholar
Shanmuganathan N, Hughes TP (2018) Molecular monitoring in CML: how deep? How often? How should it influence therapy? Hematol Am Soc Hematol Educ Program 2018(1):168–176
Google Scholar
Branford S (2020) Why is it critical to achieve a deep molecular response in chronic myeloid leukemia? Haematologica 105(12):2730–2737
CAS
PubMed
PubMed Central
Google Scholar
Miura T, Yasuda S, Sato Y (2021) A simple method to estimate the in-house limit of detection for genetic mutations with low allele frequencies in whole-exome sequencing analysis by next-generation sequencing. BMC Genom Data 22(1):8
PubMed
PubMed Central
Google Scholar
Soverini S, Abruzzese E, Bocchia M, Bonifacio M, Galimberti S, Gozzini A et al (2019) Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. J Hematol OncolJ Hematol Oncol 12:131
Google Scholar
Soverini S, Bavaro L, De Benedittis C, Martelli M, Iurlo A, Orofino N et al (2020) Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood 135(8):534–541
PubMed
Google Scholar
Curik N, Polivkova V, Burda P, Koblihova J, Laznicka A, Kalina T et al (2021) Somatic mutations in oncogenes are in chronic myeloid leukemia acquired de novo via deregulated base-excision repair and alternative non-homologous end joining. Front Oncol 11:3795
Google Scholar
Soverini S, Abruzzese E, Bocchia M, Bonifacio M, Galimberti S, Gozzini A et al (2019) Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. J Hematol Oncol J Hematol Oncol 12(1):131
PubMed
Google Scholar
Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C et al (2018) Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood 132(9):948–961
CAS
PubMed
Google Scholar
Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2):117–125
CAS
PubMed
Google Scholar
Chandrasekhar C, Kumar PS, Sarma PVGK (2019) Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients. Sci Rep 9(1):2412
PubMed
PubMed Central
Google Scholar
Ko TK, Javed A, Lee KL, Pathiraja TN, Liu X, Malik S et al (2020) An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood 135(26):2337–2353
PubMed
Google Scholar
Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST et al (2019) Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia 33(8):1835–1850
PubMed
PubMed Central
Google Scholar
Goldman JM (2010) Chronic myeloid leukemia: a historical perspective. Semin Hematol 47(4):302–311
CAS
PubMed
Google Scholar
Sharf G, Marin C, Bradley JA, Pemberton-Whiteley Z, Bombaci F, Christensen RIO et al (2020) Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. Leukemia 34(8):2102–2112
PubMed
PubMed Central
Google Scholar
Westerweel PE, Te Boekhorst PAW, Levin M-D, Cornelissen JJ (2019) New approaches and treatment combinations for the management of chronic myeloid leukemia. Front Oncol 9:665
PubMed
PubMed Central
Google Scholar
Cortes J, Lang F (2021) Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol J Hematol Oncol 14(1):44
CAS
PubMed
Google Scholar
Cortes J. Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 tyrosine kinase inhibitor (TKI): activity in CML chronic phase patients failing TKI therapies including ponatinib. In ASH; 2020.
Lu M. Exposure-response (E-R) analysis of olverembatinib (HQP1351) in Chinese patients with chronic myeloid leukemia (CML). In: ASH; 2020.
Turkina A, Vinogradova O, Lomaia E, Shatokhina E, Shukhov O, Chelysheva E et al (2019) PF-114: a 4th generation tyrosine kinase-inhibitor for chronic phase chronic myeloid leukaemia including BCRABL1T315I. Blood 13(134):1638–1638
Google Scholar
Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H et al (2019) Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell 36(4):431–443
CAS
PubMed
PubMed Central
Google Scholar
Cortes J, Lang F, Kim D-W, Réa D, Mauro MJ, Minami H et al (2019) S883 combination therapy using asciminib plus imatinib (IMA) in patients (PTS) with chronic myeloid leukemia (CML): results from a phase 1 study. HemaSphere 3(S1):397
Google Scholar
Hochhaus A, Boquimpani C, Rea D, Minami Y, Lomaia E, Voloshin S et al (2020) Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs). Blood 136:LBA4
Google Scholar
Hughes T, Mauro M, Cortes J, Minami H, Rea D, DeAngelo D et al (2019) Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 12(381):2315–2326
Google Scholar
Hughes T et al (2020) CML-121: efficacy and safety of asciminib in heavily pretreated patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) with sensitivity to tyrosine kinase inhibitors (TKIs). Clin Lymphoma Myeloma Leukemia 20:S235
Google Scholar
Muselli F, Peyron J-F, Mary D (2019) Druggable biochemical pathways and potential therapeutic alternatives to target leukemic stem cells and eliminate the residual disease in chronic myeloid leukemia. Int J Mol Sci 20(22):5616
CAS
PubMed Central
Google Scholar
Özgür Yurttaş N, Eşkazan AE (2020) Novel therapeutic approaches in chronic myeloid leukemia. Leuk Res 91:106337
PubMed
Google Scholar
Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T et al (2020) Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol 95(11):1288–1295
CAS
PubMed
Google Scholar
Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K et al (2020) Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with philadelphia chromosome-positive advanced myeloid leukemias. Acta Haematol 143(6):567–573
CAS
PubMed
Google Scholar
Atallah E, Schiffer CA (2020) Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: When and for whom? Haematologica 105(12):2738–2745
CAS
PubMed
PubMed Central
Google Scholar
Chen K, Du T, Xiong P, Fan G, Yang W (2019) Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia with losing major molecular response as a definition for molecular relapse: a systematic review and meta-analysis. Front Oncol 9:372
PubMed
PubMed Central
Google Scholar
Rousselot P, Loiseau C, Delord M, Cayuela JM, Spentchian M (2020) Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission. Blood Adv 4(13):3034–3040
CAS
PubMed
PubMed Central
Google Scholar
Merli P, Ifversen M, Truong TH, Marquart HV, Buechner J, Wölfl M et al (2021) Minimal residual disease prior to and after haematopoietic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia: What level of negativity is relevant? Front Pediatr 9:1279
Google Scholar
Aijaz J, Junaid N, Asif Naveed M, Maab R (2020) Risk stratification of chronic myeloid leukemia according to different prognostic scores. Cureus 12(3):e7342
PubMed
PubMed Central
Google Scholar
Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S et al (2020) The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia 34(8):2138–2149
PubMed
PubMed Central
Google Scholar
Taylor M, Khan S, Stapleton M, Wang J, Chen J, Wynn R et al (2019) Hematopoietic stem cell transplantation for mucopolysaccharidoses; past, present, and future. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 25(7):e226
Google Scholar
Jabbour E, Kantarjian H (2020) Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol 95(6):691–709
CAS
PubMed
Google Scholar